Nothing Special   »   [go: up one dir, main page]

CL2011000295A1 - Compuestos derivados de pirimidil-amino-benzamida; inhibidores de tirosin-quinasa; y su uso en el tratamiento de la hipertension pulmonar. - Google Patents

Compuestos derivados de pirimidil-amino-benzamida; inhibidores de tirosin-quinasa; y su uso en el tratamiento de la hipertension pulmonar.

Info

Publication number
CL2011000295A1
CL2011000295A1 CL2011000295A CL2011000295A CL2011000295A1 CL 2011000295 A1 CL2011000295 A1 CL 2011000295A1 CL 2011000295 A CL2011000295 A CL 2011000295A CL 2011000295 A CL2011000295 A CL 2011000295A CL 2011000295 A1 CL2011000295 A1 CL 2011000295A1
Authority
CL
Chile
Prior art keywords
pyrimidyl
benzamide
amino
treatment
compounds derived
Prior art date
Application number
CL2011000295A
Other languages
English (en)
Inventor
Steve Quinn Deborah Pascoe
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41137217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011000295(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2011000295A1 publication Critical patent/CL2011000295A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Compuestos derivados de pirimidil-amino-benzamida; y su uso para el tratamiento de la hipertensión arterial pulmonar.
CL2011000295A 2008-08-13 2011-02-11 Compuestos derivados de pirimidil-amino-benzamida; inhibidores de tirosin-quinasa; y su uso en el tratamiento de la hipertension pulmonar. CL2011000295A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8838208P 2008-08-13 2008-08-13
US16450109P 2009-03-30 2009-03-30

Publications (1)

Publication Number Publication Date
CL2011000295A1 true CL2011000295A1 (es) 2011-07-15

Family

ID=41137217

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011000295A CL2011000295A1 (es) 2008-08-13 2011-02-11 Compuestos derivados de pirimidil-amino-benzamida; inhibidores de tirosin-quinasa; y su uso en el tratamiento de la hipertension pulmonar.

Country Status (16)

Country Link
US (1) US20110190313A1 (es)
EP (1) EP2315592A1 (es)
JP (1) JP2011530607A (es)
KR (1) KR20110053354A (es)
CN (1) CN102123711A (es)
AU (1) AU2009282104A1 (es)
BR (1) BRPI0917491A2 (es)
CA (1) CA2732789A1 (es)
CL (1) CL2011000295A1 (es)
IL (1) IL210922A0 (es)
MA (1) MA32617B1 (es)
MX (1) MX2011001668A (es)
NZ (1) NZ590839A (es)
RU (1) RU2011109078A (es)
TW (1) TW201010999A (es)
WO (1) WO2010019540A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3130908A1 (en) 2009-06-30 2010-12-30 Mallinckrodt Hospital Products IP Limited Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
ES2675720T3 (es) 2013-01-10 2018-07-12 Pulmokine, Inc. Inhibidores de quinasa no selectivos
EP3782604A1 (en) 2013-07-31 2021-02-24 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
ES2959419T3 (es) 2013-10-11 2024-02-26 Pulmokine Inc Formulaciones secas por aspersión
RU2763525C2 (ru) 2016-10-27 2021-12-30 Пульмокин, Инк. Комбинированная терапия для лечения легочной гипертензии
MX2019005401A (es) 2016-11-08 2019-08-05 Reata Pharmaceuticals Inc Metodos para tratar el sindrome de alport con bardoxolona metilo o analogos de la misma.
US11229650B2 (en) 2019-05-16 2022-01-25 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
US11464776B2 (en) 2019-05-16 2022-10-11 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
WO2021108303A1 (en) * 2019-11-25 2021-06-03 PHPrecisionMed, LLC Pharmaceutical compositions for the treatment of pulmonary hypertension
CA3199324A1 (en) 2020-11-17 2022-05-27 Adam Marc Silverstein Inhaled imatinib for pulmonary hypertension field

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
JP4942297B2 (ja) * 2002-10-25 2012-05-30 ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド 肺高血圧症の処置を目的としたｎ−｛５−［４−（４−メチルピペラジノメチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリジン−アミンの使用
GB0325031D0 (en) * 2003-10-27 2003-12-03 Novartis Ag Organic compounds
ES2373912T3 (es) * 2005-01-28 2012-02-10 Novartis Ag Uso de pirimidilaminobenzamidas para el tratamiento de enfermedades que responden a la modulación de la actividad de quinasa tie-2.
EP1879584B1 (en) * 2005-05-02 2016-06-22 Novartis AG Pyrimidylaminobenzamide derivatives for hypereosinophilic syndrome
PT1959957E (pt) * 2005-12-06 2012-10-29 Novartis Ag Derivados de pirimidilaminobenzamida para o tratamento de neurofibromatose
CA2668190A1 (en) * 2006-11-03 2008-05-15 Irm Llc Compounds and compositions as protein kinase inhibitors

Also Published As

Publication number Publication date
EP2315592A1 (en) 2011-05-04
WO2010019540A1 (en) 2010-02-18
CA2732789A1 (en) 2010-02-18
IL210922A0 (en) 2011-04-28
AU2009282104A1 (en) 2010-02-18
KR20110053354A (ko) 2011-05-20
RU2011109078A (ru) 2012-09-20
US20110190313A1 (en) 2011-08-04
BRPI0917491A2 (pt) 2015-12-01
JP2011530607A (ja) 2011-12-22
MX2011001668A (es) 2011-03-25
NZ590839A (en) 2013-02-22
MA32617B1 (fr) 2011-09-01
CN102123711A (zh) 2011-07-13
TW201010999A (en) 2010-03-16

Similar Documents

Publication Publication Date Title
CL2011000295A1 (es) Compuestos derivados de pirimidil-amino-benzamida; inhibidores de tirosin-quinasa; y su uso en el tratamiento de la hipertension pulmonar.
CY2017012I2 (el) Αναστολεις κινασης τυροσινης bruton
CL2008002478A1 (es) Compuestos derivados de n-fenil-5-(4 haloalcoxi)fenil) pirimidin-2-amino, inhibidores de c-kit y pdgfr; composicion farmaceutica; y su uso en el tratmiento de asma, dermatitis atopica, hipertension pulmonar o arterial, fibrosis renal, pulmonar o cardiaca, entre otras.
EA201000094A1 (ru) Производные пиримидинил-пиридазинона
CR20120244A (es) Inhibidores de la tirosina quinasa de bruton
EA200870409A1 (ru) Антагонисты киназы pi3
BRPI0816064A2 (pt) Inibidores da atividade de proteína tirosina cinase.
BRPI0922224A2 (pt) composições de inibidores de proteína tirosina quiinase receptora.
CL2010001483A1 (es) Compuestos derivados de 5-fenil-1h-piridin-2-ona y 6-fenil-2h-piridazin-3-ona, inhibidores de tirosina-quinasa (btk); composicion farmaceutica que comprende a dichos compuestos y su uso para el tratamiento de un estado patologico inflamatorio y/o autoinmune.
BRPI0810086A2 (pt) inibidores de tirosina quinase de bruton
NO20081636L (no) FAP - inhibitorer
BRPI0915231A2 (pt) compostos inibidores de quinase e métodos de uso
CL2011001215A1 (es) Compuestos derivados de pirimidina, inhibidores de tirosina quinasa; composiciones farmaceuticas que los comprenden; y su uso en el tratamiento y/o prevencion de cancer, enfermedades inflamatorias y enfermedades autoinmunes.
EA201100966A1 (ru) Производные пиридазинона
CL2011001333A1 (es) Compuestos derivados de heterociclos nitrogenados sustituidos, inhibidores de ns5a; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
EA201100306A1 (ru) Производные циклогексиламида и их применение в качестве антагонистов рецептора crf-1
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
AP2012006166A0 (en) Pyrimidine derivatives as protein tyrosine kinase 2 inhibitors.
CY2016017I1 (el) Συνθεση για θεραπεια πνευμονικης υπερτασης
CL2008001234A1 (es) Compuestos derivados de heterociclos nitrogenados, inhibidores de las proteinas de apoptosis; y uso en el tratamiento del cancer.
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
EA201170052A1 (ru) Производные тиофена или тиазола и их применение как ингибиторов pi3k
EA201001648A1 (ru) Производные пиридазинона
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
ZA200709000B (en) Substituted oxazole derivatives and their use as tyrosine kinase inhibitors